Levivier M, Gash D M, Przedborski S
Department of Neurosurgery, Université Libre de Bruxelles-Hôpital Erasme, Belgium.
Neuroscience. 1995 Nov;69(1):43-50. doi: 10.1016/0306-4522(95)00230-g.
Injection of quinolinic acid in the rat striatum mimics neurochemical changes observed in Huntington's disease. We previously demonstrated that intrastriatal transplantation of fetal striatum or gelfoam protects against toxicity induced by a subsequent intrastriatal injection of quinolinic acid performed one week later. Herein, we examined whether fetal striatum or sham transplantation provides protection against quinolinic acid that lasts up to four weeks. Intrastriatal quinolinic acid injection produces neuronal loss and gliosis in Nissl staining, loss of cytochrome oxidase histochemical staining, decrease in autoradiographic binding of [3H]SCH 23390-labeled dopamine D1 and [3H]CGS 21680-labeled adenosine A2 receptors, and increase in autoradiographic binding of [3H]PK 11195-labeled peripheral benzodiazepine binding sites. None of these changes was observed in rats transplanted with fetal striatum one, two or four weeks before quinolinic acid injection. In animals transplanted with fetal striatal tissue, Nissl staining showed healthy grafts located in normal appearing striata. Although sham transplantation performed one week before quinolinic acid injection also protected against histological, histochemical and binding changes, sham transplantation performed two or four weeks before quinolinic acid injection was less effective in attenuating quinolinic acid-induced striatal toxicity. Thus, sham transplantation provides transient protection against quinolinic acid-induced striatal toxicity, whereas implantation of tissue such as fetal striatum seems to be required for long-lasting protection. Our study suggests that intracerebral transplantation may also act through other mechanisms than restoration of deficient neurotransmitters or damaged pathways, a finding which may have significant clinical implications in assessing the potential benefit of this approach for the treatment of neurodegenerative disorders such as Huntington's disease.
向大鼠纹状体内注射喹啉酸可模拟在亨廷顿病中观察到的神经化学变化。我们之前证明,在一周后进行纹状体内注射喹啉酸时,向纹状体内移植胎儿纹状体或明胶海绵可预防其诱导的毒性。在此,我们研究了胎儿纹状体移植或假移植是否能提供长达四周的针对喹啉酸的保护作用。纹状体内注射喹啉酸会导致尼氏染色显示神经元丢失和胶质细胞增生、细胞色素氧化酶组织化学染色丧失、[3H]SCH 23390标记的多巴胺D1和[3H]CGS 21680标记的腺苷A2受体的放射自显影结合减少,以及[3H]PK 11195标记的外周苯二氮䓬结合位点的放射自显影结合增加。在喹啉酸注射前一、二或四周移植胎儿纹状体的大鼠中未观察到这些变化。在移植了胎儿纹状体组织的动物中,尼氏染色显示健康的移植物位于外观正常的纹状体内。尽管在喹啉酸注射前一周进行的假移植也能预防组织学、组织化学和结合变化,但在喹啉酸注射前两周或四周进行的假移植在减轻喹啉酸诱导的纹状体毒性方面效果较差。因此,假移植可提供针对喹啉酸诱导的纹状体毒性的短暂保护,而植入诸如胎儿纹状体等组织似乎是实现长期保护所必需的。我们的研究表明,脑内移植可能还通过除恢复缺乏的神经递质或受损通路之外的其他机制起作用,这一发现可能对评估这种方法治疗亨廷顿病等神经退行性疾病的潜在益处具有重要的临床意义。